Chemistry:Sparsentan
From HandWiki
Short description: Medication
 | |
| Clinical data | |
|---|---|
| Trade names | Filspari |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623018 |
| License data |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEBI | |
| Chemical and physical data | |
| 3D model (JSmol) | |
| |
| |
Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy.[1] Sparsentan is an endothelin and angiotensin II receptor antagonist.[1][2] It is taken by mouth.[1]
It was approved for medical use in the United States in February 2023.[1][3][4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[5]
Medical uses
Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.[1]
Society and culture
Legal status
Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Filspari- sparsentan tablet, film coated". 17 February 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7354af1-f304-f4d9-e053-2995a90ab219.
- ↑ "Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist". The Annals of Pharmacotherapy: 10600280231198925. September 2023. doi:10.1177/10600280231198925. PMID 37706310.
- ↑ "Travere Therapeutics Announces FDA Accelerated Approval of Filspari (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy" (Press release). Travere Therapeutics. 17 February 2023. Retrieved 17 February 2023 – via GlobeNewswire.
- ↑ "Sparsentan: First Approval". Drugs 83 (6): 563–568. April 2023. doi:10.1007/s40265-023-01864-x. PMID 37022667.
- ↑ (PDF) New Drug Therapy Approvals 2023 (Report). January 2024. https://www.fda.gov/media/175253/download. Retrieved 9 January 2024.
External links
- Clinical trial number NCT03762850 for "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)" at ClinicalTrials.gov
 |  |
